Article Details
Retrieved on: 2022-05-12 23:50:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company has launched PHESGO the first ever fixed dose formulation in oncology to combine two monoclonal antibodies – Perjeta (pertuzumab) and ...
Article found on: www.moneycontrol.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here